Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
Authors:
- 1 April 2013
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 24 (4) , 422-425
Abstract
The role of pazopanib in the second-line setting of refractory metastatic transitional cell carcinoma of the urothelium has not been defined clearly. The aim of this phase I/II trial was to assess the safety, tolerability, and efficacy of combining pazopanib and vinflunine in patients with metastatic transitional cell carcinoma of the urothelium after failure of first-line platinum-containing therapy. From May 2011 to December 2011, five patients were enrolled in this trial. Pazopanib was the investigated compound; four levels were planned (200, 400, 600, and 800 mg/day). Vinflunine was dosed at 280 mg/m2 for the first dose and 320 mg/m2 every 3 weeks thereafter. After the definition of a tolerated dose for the combined therapy, a subsequent phase II study was planned. At the starting level, pazopanib 200 mg/day, dose-limiting toxicities were observed in two of five patients. One patient experienced grade 4 febrile neutropenia, which led to treatment discontinuation. A second patient showed grade 3 hepatobiliary disorder with an increase in γ-glutamyltransferase. The study was interrupted at dose level 1 for safety reasons. The initially planned phase II study was therefore not carried out. This phase I study showed that combined therapy of daily pazopanib (200 mg) and vinflunine (280/320 mg/m2) every 3 weeks is poorly tolerated in patients with refractory advanced urothelial cancer.Keywords
This publication has 23 references indexed in Scilit:
- Pazopanib Synergizes with Docetaxel in the Treatment of Bladder Cancer CellsUrology, 2011
- A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancerBreast Cancer Research and Treatment, 2011
- A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumorsInvestigational New Drugs, 2010
- Phase I trial of vinflunine and pemetrexed in refractory solid tumorsInvestigational New Drugs, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapyCancer, 2007
- Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer PatientsJournal of Thoracic Oncology, 2006
- Correlation of Metastasis Related Gene Expression and Relapse-Free Survival in Patients With Locally Advanced Bladder Cancer Treated With Cystectomy and ChemotherapyJournal of Urology, 2004
- Some practical improvements in the continual reassessment method for phase I studiesStatistics in Medicine, 1995
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993